Publication date: Available online 15 October 2020Source: TalantaAuthor(s): Andrei M. Surkov, Rodrigo G. Queiroz, Rafael S. Rinco, Alejandro G. Rios Ivano G. R. Gutz, Alexandre L.B. Baccaro, Lúcio Angnes
Thu Oct 15, 2020 13:18
Publication date: Available online 15 October 2020Source: TalantaAuthor(s): A. Ballester-Caudet, L. Hakobyan, Y. Moliner-Martinez, C. Molins-Legua, P. Campíns-Falcó
Thu Oct 15, 2020 13:18
Publication date: Available online 15 October 2020Source: TalantaAuthor(s): Jacob Bothen, Dirk Wallschläger
Thu Oct 15, 2020 13:18
Publication date: Available online 15 October 2020Source: TalantaAuthor(s): Fenglong Jiao, Fangyuan Gao, Yuanyuan Liu, Zhiya Fan, Xiaochao Xiang, Chaoshuang Xia, Yayao Lv, Yuping Xie, Haihong Bai, Wanjun Zhang, Weijie Qin, Xiaohong Qian
Thu Oct 15, 2020 13:18
Publication date: Available online 15 October 2020Source: TalantaAuthor(s): Quinn T. Birch, Phillip M. Potter, Patricio X. Pinto, Dionysios D. Dionysiou, Souhail R. Al-Abed
Thu Oct 15, 2020 13:18
Publication date: February 2021Source: Current Opinion in Neurobiology, Volume 66Author(s): Orly Reiner, Arpan Parichha, Tamar Sapir
Thu Oct 15, 2020 13:14
Publication date: Available online 14 October 2020Source: Journal of VoiceAuthor(s): Neda Azizi Ata, Seyyedeh Maryam Khoddami, Arash Babaei-Ghazani, Farzad Izadi, Saman Maroufizadeh
Thu Oct 15, 2020 13:14
Publication date: Available online 14 October 2020Source: Journal of VoiceAuthor(s): Łukasz Piotr Pawelec, Katarzyna Graja, Anna Lipowicz
Thu Oct 15, 2020 13:14
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Maria V. Deligiorgi, Dimitrios T. Trafalis
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): ZhengXia Zhong, JiaXing Tan, Li Tan, Yi Tang, ZhiCheng Qiu, GaiQin Pei, Wei Qin
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Tooba Ghazanfari, Amir Hossein Norooznezhad, Shima Javidan, Leila Norouz, Azadeh Farzanehdoust, Kamran Mansouri, Mohammad Hossein Ahmadi, Shayan Mostafaei, Pouya Javadian, Mahdi Sheikh, Sedigheh Hantoushzadeh
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Yandong Miao, Jiangtao Wang, Qiutian Li, Wuxia Quan, Yingying Wang, Chen Li, Jingjing Wu, Denghai Mi
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Si-wei Wang, Wen Wang, Hao Sheng, Yong-feng Bai, Yuan-yuan Weng, Xue-yu Fan, Fang Zheng, Xin-tian Zhu, Zheng-cai Xu, Feng Zhang
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Dongyang Zhao, Zhe Li, Xiandong Liu, Na Liu, Xiaowei Bao, Hong Sun, Qinshu Meng, Huijuan Ren, Jianwen Bai, Xiaohui Zhou, Lunxian Tang
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Li Li, Zhihai Wu, Min Wu, Xuan Qiu, Yue Wu, Zhihui Kuang, Li Wang, Ta Sun, Yang Liu, Shuai Yi, Hua Jing, Shuaixiang Zhou, Bingliang Chen, Dongdong Wu, Weiwei Wu, Junjian Liu
Thu Oct 15, 2020 13:10
Comprehensive analysis of the expression and prognostic value of CXC chemokines in colorectal cancer
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Li Yu, Xinmei Yang, Chuchu Xu, Jiachun Sun, Zhipeng Fang, Hongming Pan, Weidong Han
Thu Oct 15, 2020 13:10
Publication date: December 2020Source: International Immunopharmacology, Volume 89, Part BAuthor(s): Fei-fei Han, Ming-xia Fang, Dan-tong Zhao, Yi-chao Dong, Guo-Hong Yuan, Jian-en Gao, Chang-long Guo
Thu Oct 15, 2020 13:10
Abstract The incidence of intrahepatic cholangiocarcinoma (iCCA) continues to increase worldwide, however its molecular pathogenesis remains poorly understood. Recent studies have implicated microRNAs in iCCA progression. In this study, we demonstrated that miR‐885‐5p was significantly decreased in iCCA tissues. Downregulation of miR‐885‐5p was correlated with vascular invasion, lymph node metastasis, unfavorable overall survival, and shorter disease‐free survival. Silencing or overexpressing miR‐885‐5p...
Wed Oct 14, 2020 15:40
Publication date: December 2020Source: Photodiagnosis and Photodynamic Therapy, Volume 32Author(s): Ida M. Heerfordt, Catharina M. Lerche, Hans Christian Wulf
Thu Oct 15, 2020 12:49
Publication date: Available online 15 October 2020Source: Photodiagnosis and Photodynamic TherapyAuthor(s): Souad A. Elfeky, Ahmed Elsayed, Mahmoud Moawad, Wafaa A. Ahmed
Thu Oct 15, 2020 12:49
Publication date: Available online 14 October 2020Source: Photodiagnosis and Photodynamic TherapyAuthor(s): Ardavan Etemadi, Saba Eftfkhari Bayati, Maryam Pourhajibagher, Nasim Chiniforoush
Thu Oct 15, 2020 12:49
Publication date: Available online 14 October 2020Source: Photodiagnosis and Photodynamic TherapyAuthor(s): Arash Safari, Abolfazl Sarikhani, Daryoush Shahbazi-Gahrouei, Zahra Alamzadeh, Jaber Beik, Amin Shiralizadeh Dezfuli, Vahid Pirhajati Mahabadi, Maryam Tohfeh, Ali Shakeri-Zadeh
Thu Oct 15, 2020 12:49
Publication date: Available online 14 October 2020Source: Photodiagnosis and Photodynamic TherapyAuthor(s): C Ganss, A Glanz, T Glanz, N Schlueter, S Ruf
Thu Oct 15, 2020 12:49
Abstract Differential diagnosis in non-traumatic acute abdomen is broad and unrelated diseases may simulate each other from a clinical perspective. Despite the fact that they are not as common, acute abdominal pain due to diseases related to visceral vessels may be life-threating if not detected and treated promptly. Thrombosis, dissection, and aneurysm in the abdominal visceral arteries or thrombosis in visceral veins may cause acute abdominal pain. Imaging with appropriate...
Thu Oct 15, 2020 03:00
Abstract Acute or chronic non-neoplastic diffuse mediastinal diseases have multiple causes, degrees of severity, and a wide range of management. Some situations require emergency care while others do not need specific treatment. Although the diagnosis may be suspected on chest X-ray, it is mainly based on CT. A delayed recognition is not uncommonly observed. Some findings may prompt the radiologist to look for specific associated injuries or lesions. This...
Thu Oct 15, 2020 03:00
Abstract Persistent left superior vena cava (PLSVC) is the most common thoracic venous anomaly and may be a component of the complex cardiac pathologies. While it is often asymptomatic, it can lead to significant problems such as arrhythmias and cyanosis. Besides, it can cause serious complications during vascular interventional procedures or the surgical treatment of cardiac anomalies (CA). The clinical significance of PLSVC depends on the drainage site and the accompanying...
Thu Oct 15, 2020 03:00
Abstract ObjectiveCognitive complaints are more frequent in women with breast cancer (BC) than in healthy controls and can be present before any treatment. Findings regarding contributive factors remain inconsistent. This study aimed to identify different groups of patients with cognitive complaints at BC diagnosis and to determine whether these different groups were associated with demographic, medical or psychological characteristics.MethodsCognitive complaints were assessed in a subset of 264...
Wed Oct 14, 2020 17:57
ABSTRACT Background Despite evidence for the protective effects of early regular exposure to peanut and egg proteins against allergies, the optimal timing of cow’s milk (CM) protein exposure is unknown. Objective We aimed to determine when during the first year of life CM‐based formula consumption becomes associated with lower CM allergy (CMA) risk. Methods We used the dataset of the Japan Environment and Children’s Study (JECS), a nationwide birth cohort involving over 100,000 mother‐child...
Wed Oct 14, 2020 22:00
Abstract Background Asthma is common worldwide and a large part of subjects with asthma have concomitant allergic multimorbidity in the form of rhinitis and/or eczema. Objective The aim of this study is to investigate if the presence of allergic multimorbidity in asthma relates to allergic sensitisation, allergic and respiratory symptoms, quality of life, inflammatory markers, lung function, use of medication and background factors. Methods A total of 437 asthmatics from the (GA2LEN)...
Wed Oct 14, 2020 20:00
Abstract Although the genome of the Streptomyces model strain S. coelicolor was sequenced nearly two decades ago, the function of many annotated genes has not been verified, including that of gene sco1979, which was predicted to encode a transcriptional regulator of the xenobiotic response element (XRE) family. In this study, we showed that SCO1979 represses its own transcription and that deletion of sco1979 from S. coelicolor markedly enhanced production...
Thu Oct 15, 2020 03:00
Abstract The polyene macrolide rimocidin, produced by Streptomyces rimosus M527, was found to be highly effective against a broad range of fungal plant pathogens. Current understanding of the regulatory mechanism of rimocidin biosynthesis and morphological differentiation in S. rimosus M527 is limited. NsdA is considered a negative regulator involved in morphological differentiation and biosynthesis of secondary metabolites in some Streptomyces species....
Thu Oct 15, 2020 03:00
The large majority of patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have mild or no symptoms, whereas a small proportion of patients have respiratory compromise, acute respiratory distress syndrome, and multiorgan failure (which is often fatal). The…
Thu Oct 15, 2020 03:00
Autophagy ("self-eating") is the process through which parts of the cell are degraded in the lysosome. Elucidation of the key genes essential for autophagy — originally identified in yeast — has led to a new era in our understanding of mammalian physiology and the pathophysiology of human diseases.…
Thu Oct 15, 2020 03:00
Abstract Lower third molar removal is the most commonly performed dental surgical procedure. Nevertheless, it is difficult to ensure that all the informed consent forms given to patients are based on the best evidence as many newer publications could change the conclusions of previous research. Therefore, the goal of this review paper is to cover existing meta‐analyses, randomized control trials, and related articles in order to collect data for improved and more current informed consent.
Wed Oct 14, 2020 20:50
Abstract Introduction: Iatrogenic nerve injury during surgery is a major source of concern for both patients and surgeons. This study aimed to identify the nerves most commonly injured during surgery, along with the commonly associated operative procedures. Materials and Methods: A literature search was conducted using the PubMed database to identify nerves commonly injured during surgery, along with the surgical procedure associated with the injury. Results: The following eleven nerves, ranked...
Wed Oct 14, 2020 11:43
Abstract Background We aimed to compare unstimulated saliva flow using 3‐minute modified Schirmer test (MST) following bilateral vs unilateral radiotherapy (RT) in oropharyngeal carcinoma (OPC). Methods We reviewed OPC patients treated with definitive intensity‐modulated radiation therapy (IMRT) between 2011 and 2017. MST was measured at baseline, 1‐/6‐/12‐/24‐month post‐RT. MST values were compared between bilateral‐RT vs unilateral‐RT groups. Multivariable logistic regression analysis...
Thu Oct 15, 2020 11:41
Abstract Background To assess long‐term donor site morbidity after radial forearm free (RFF) flap harvesting. Methods Enrolled patients were asked to complete the Disability of the Arm, Shoulder, and Hand (DASH) questionnaire and undergo wrist motion and hand strength examinations at different time points. The data were prospectively collected and retrospectively analyzed. Results The postoperative DASH score did not return to normal until 24 months after the operation. The mean postoperative...
Thu Oct 15, 2020 11:41
New England Journal of Medicine, Ahead of Print.
Wed Oct 14, 2020 12:01
New England Journal of Medicine, Ahead of Print.
Wed Oct 14, 2020 12:00
New England Journal of Medicine, Volume 383, Issue 16, Page 1577-1577, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1588-1589, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1501-1503, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1507-1509, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1503-1505, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1592-1594, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1594-1596, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1535-1543, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1564-1576, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1596-1598, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1511-1521, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1590-1591, October 2020.
Wed Oct 14, 2020 11:55
New England Journal of Medicine, Volume 383, Issue 16, Page 1578-1586, October 2020.
Wed Oct 14, 2020 11:55
Abstract Recent findings have found that the influenza vaccine induces changes in the immune system in favor of anti‐tumor cytotoxicity. The aim in this study was to investigate if an influenza vaccine given in the postoperative period decreased overall and cancer‐specific mortality in patients undergoing curative surgery for solid cancers. We conducted a registry‐based national observational study in Denmark in the period January 1, 2010 to December 31, 2015 with a follow‐up period of 3 years starting...
Wed Oct 14, 2020 21:30
The Role of Environmental Exposures in Atopic Dermatitis. Curr Allergy Asthma Rep. 2020 Oct 12;20(12):74 Authors: Narla S, Silverberg JI Abstract PURPOSE OF REVIEW: Although genetic factors clearly play a role in the development of atopic dermatitis (AD), the recent dramatic increase in the prevalence of AD in low- and middle-income countries is not consistent with only a role of genetic factors. These findings strongly suggest that environmental...
Thu Oct 15, 2020 10:48
PrOTYPE is a locked down assay validated to Institute of Medicine standards, using NanoString technology to classify high-grade serous ovarian cancer into four defined subgroups. Future directions will include prospective–retrospective analysis and prospective clinical validation to define the predictive role of this assay and its role in influencing treatment decisions. See related article by Talhouk et al., p. 5411
Thu Oct 15, 2020 10:05
Purpose: Malignant pleural mesothelioma (MPM) is considered an orphan disease with few treatment options. Despite multimodality therapy, the majority of MPMs recur and eventually become refractory to any systemic treatment. One potential mechanism underlying therapeutic resistance may be intratumor heterogeneity (ITH), making MPM challenging to eradicate. However, the ITH architecture of MPM and its clinical impact have not been well studied. Experimental Design: We delineated the immunogenomic...
Thu Oct 15, 2020 10:05
IL15 and TIGIT blockade enhances the natural killer (NK) cell–mediated activity against MHC-I–deficient melanoma both in vitro and in preclinical models. IL15-induced harnessing of NK cells, associated with their unleashing by TIGIT blockade, may represent a therapeutic approach for tumors, which lack HLA-I molecules thus escaping the CD8+ T cell–mediated control. See related article by Chauvin et al., p. 5520
Thu Oct 15, 2020 10:05
Purpose: Bevacizumab is considered a promising therapy for brain necrosis after radiotherapy, while some patients fail to derive benefit or even worsen. Hence, we developed and validated a radiomics model for predicting the response to bevacizumab in patients with brain necrosis after radiotherapy. Experimental Design: A total of 149 patients (with 194 brain lesions; 101, 51, and 42 in the training, internal, and external validation sets, respectively) receiving bevacizumab were enrolled....
Thu Oct 15, 2020 10:05
Liver cancer is the fourth leading cause of cancer-related mortality worldwide and incidence is on the rise. Hepatocellular carcinoma (HCC) is the most common form of liver cancer, with a complex etiology and limited treatment options. The standard-of-care treatment for patients with advanced HCC is sorafenib, a tyrosine kinase inhibitor that offers limited survival benefit. In the past years, therapeutic options for the treatment of advanced HCC have increased substantially, including additional...
Thu Oct 15, 2020 10:05
Purpose: Natural killer (NK) cells play a critical role in tumor immunosurveillance. Multiple activating and inhibitory receptors (IR) regulate NK-cell–mediated tumor control. The IR T-cell immunoglobulin and ITIM domain (TIGIT) and its counter-receptor CD226 exert opposite effects on NK-cell–mediated tumor reactivity. Experimental Design: We evaluated the frequency, phenotype, and functions of NK cells freshly isolated from healthy donors and patients with melanoma with multiparameter flow...
Thu Oct 15, 2020 10:05
Glioblastoma (WHO grade IV glioma) is the most common malignant primary brain tumor in adults. Survival has remained largely static for decades, despite significant efforts to develop new effective therapies. Immunotherapy and especially immune checkpoint inhibitors and programmed cell death (PD)-1/PD-L1 inhibitors have transformed the landscape of cancer treatment and improved patient survival in a number of different cancer types. With the exception of few select cases (e.g., patients with Lynch...
Thu Oct 15, 2020 10:05
Purpose: Gene expression–based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, evaluation of clinical utility has been hindered by nonstandardized methods, which are not applicable in a clinical setting. We sought to generate a clinical grade minimal gene set assay for classification of individual tumor specimens into HGSOC subtypes and confirm previously reported...
Thu Oct 15, 2020 10:05
Despite standard of care for glioblastoma, including gross total resection, high-dose radiation, and dose-limited chemotherapy, this tumor remains one of the most aggressive and therapeutically challenging. The relatively small number of patients with this diagnosis compared with more common solid tumors in clinical trials commits new glioblastoma therapies to testing in small, underpowered, nonrandomized settings. Among approximately 200 registered glioblastoma trials identified between 2005 and...
Thu Oct 15, 2020 10:05
Purpose: In both the IMpassion 130 trial in the metastatic setting and in Keynote 522 in the neoadjuvant setting, patients with triple-negative breast cancer (TNBC) showed benefit from PD-1 axis immunotherapy. Here, we assess PD-L1 expression on both tumor and immune cells using quantitative immunofluorescence to assess association with benefit from neoadjuvant durvalumab concurrent with chemotherapy in TNBC. Experimental Design: Pretreatment core needle biopsies (n = 69) were obtained from...
Thu Oct 15, 2020 10:05
The tumor suppressor p53 exerts pivotal roles in hematopoietic stem cell (HSC) homeostasis. Mutations of the TP53 gene have recently been described in individuals with clonal hematopoiesis conferring substantial risk of developing blood cancers. In patients with acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), TP53 aberrations—mutations, deletions, and a combination thereof—are encountered at a constant frequency of approximately 10%. These aberrations affect HSCs transforming them...
Thu Oct 15, 2020 10:05
Purpose: T-cell recruitment, survival, and proliferation are the important limitations to chimeric antigen receptor (CAR) T cells therapy in the treatment of solid tumors. In this study, we engineered CAR-T cells to coexpress cytokines IL7 and CCL21 (7 x 21 CAR-T), a cytokine combination in order to improve proliferation and chemotaxis of CAR-T cells. Experimental Design: CLDN18.2-specific second-generation CAR-T cells coexpressing cytokines were prepared using retroviral vector transduction....
Thu Oct 15, 2020 10:05
Purpose: The primary objective was to evaluate intracranial objective response rate (iORR) in patients receiving abemaciclib with brain or leptomeningeal metastases (LM) secondary to hormone receptor–positive (HR+) metastatic breast cancer (MBC). Secondary objectives evaluated extracranial response, abemaciclib pharmacokinetics, brain metastases tissue exposure, and safety. Patients and Methods: This nonrandomized, phase II study (NCT02308020) enrolled patients in tumor subtype–specific...
Thu Oct 15, 2020 10:05
Purpose: Induction cisplatin and gemcitabine chemotherapy is a standard treatment for locally advanced nasopharyngeal carcinoma (NPC). Inhibition of VEGF axis has been shown to promote maturation of microvasculature and improve perfusion. We conducted a four-arm study to assess the effect of two doses of either sunitinib or bevacizumab with chemotherapy in NPC. Patients and Methods: Patients with treatment-naïve locally advanced NPC were treated with three cycles of 3-weekly cisplatin and...
Thu Oct 15, 2020 10:05
Purpose: Endometrioid ovarian carcinoma (ENOC) is generally associated with a more favorable prognosis compared with other ovarian carcinomas. Nonetheless, current patient treatment continues to follow a "one-size-fits-all" approach. Even though tumor staging offers stratification, personalized treatments remain elusive. As ENOC shares many clinical and molecular features with its endometrial counterpart, we sought to investigate The Cancer Genome Atlas–inspired endometrial carcinoma (EC) molecular...
Thu Oct 15, 2020 10:05
Purpose: Romidepsin dosing recommendations for patients with malignancy and varying degrees of hepatic dysfunction was lacking at the time of regulatory approval for T-cell lymphoma. We conducted a multicenter phase I clinical trial (ETCTN-9008) via the NCI Organ Dysfunction Working Group to investigate safety, first cycle MTD, and pharmacokinetic profile of romidepsin in this setting. Patients and Methods: Patients with select advanced solid tumors or hematologic malignancies were stratified...
Thu Oct 15, 2020 10:05
Purpose: Small-molecule inhibitors have had a major impact on cancer care. While treatments have demonstrated clinically promising results, they suffer from dose-limiting toxicities and the emergence of refractory disease. Considerable efforts made to address these issues have more recently focused on strategies implementing particle-based probes that improve drug delivery and accumulation at target sites, while reducing off-target effects. Experimental Design: Ultrasmall (<8 nm) core-shell...
Thu Oct 15, 2020 10:05
Purpose: ZEN-3694 is a bromodomain extraterminal inhibitor (BETi) with activity in androgen-signaling inhibitor (ASI)-resistant models. The safety and efficacy of ZEN-3694 plus enzalutamide was evaluated in a phase Ib/IIa study in metastatic castration-resistant prostate cancer (mCRPC). Patients and Methods: Patients had progressive mCRPC with prior resistance to abiraterone and/or enzalutamide. 3+3 dose escalation was followed by dose expansion in parallel cohorts (ZEN-3694 at 48 and 96...
Thu Oct 15, 2020 10:05
Purpose: To determine if a targeted exome panel utilizing matched normal DNA can accurately detect germline and somatic HLA genes in patients with synovial sarcoma (SS) and whether select HLA-A*02 genotypes are prognostic or predictive of outcome in metastatic SS. Experimental Design: Patients with metastatic SS consented to HLA typing by a Clinical Laboratory Improvement Amendments (CLIA)-certified test to determine eligibility for a clinical trial of NY-ESO-1–specific engineered T cells...
Thu Oct 15, 2020 10:05
Purpose: The recombinant fusion protein ipafricept blocks Wnt signaling, and in combination with gemcitabine and nab-paclitaxel caused tumor regression in xenografts. This phase Ib study evaluated the combination of ipafricept with nab-paclitaxel + gemcitabine in patients with untreated metastatic pancreatic adenocarcinoma (mPDAC). Patients and Methods: Dose escalation started with standard dose nab-paclitaxel + gemcitabine and ipafricept (3.5 mg/kg days 1, 15). Because of fragility fractures...
Thu Oct 15, 2020 10:05
Purpose: Pancreatic ductal adenocarcinoma (PDAC) arising in patients with a germline BRCA1 or BRCA2 (gBRCA) mutation may be sensitive to platinum and PARP inhibitors (PARPi). However, treatment stratification based on gBRCA mutational status alone is associated with heterogeneous responses. Experimental Design: We performed a seven-arm preclinical trial consisting of 471 mice, representing 12 unique PDAC patient-derived xenografts, of which nine were gBRCA mutated. From 179 patients whose...
Thu Oct 15, 2020 10:05
Purpose: Immune checkpoint blockade has demonstrated clinical benefits across multiple solid tumor types; however, resistance and relapse often occur. New immunomodulatory targets, which are highly expressed in activated immune cells, are needed. MEDI0562, an agonistic humanized mAb, specifically binds to the costimulatory molecule OX40. This first-in-human study evaluated MEDI0562 in adults with advanced solid tumors. Patients and Methods: In this phase I, multicenter, open-label, single-arm,...
Thu Oct 15, 2020 10:05
Concomitant Proton Pump Inhibitor Use and Survival in Urothelial Carcinoma Treated with Atezolizumab
Purpose: Emerging evidence indicates that gut microbiota dysbiosis can reduce the effectiveness of immune checkpoint inhibitors (ICI). Proton pump inhibitors (PPI) are known to induce gut microbiota changes. However, little is known on the effects of PPIs on outcomes with ICI therapy, and it has not been explored in urothelial cancer treatment. Experimental Design: Individual–participant data from the advanced urothelial cancer trials, IMvigor210 (single-arm atezolizumab trial, n = 429)...
Thu Oct 15, 2020 10:05
Purpose: Non–small cell lung cancer (NSCLC) is a fatal disease with poor prognosis. A membrane-bound form of Hsp70 (mHsp70) which is selectively expressed on high-risk tumors serves as a target for mHsp70-targeting natural killer (NK) cells. Patients with advanced mHsp70-positive NSCLC may therefore benefit from a therapeutic intervention involving mHsp70-targeting NK cells. The randomized phase II clinical trial (EudraCT2008-002130-30) explores tolerability and efficacy of ex vivo–activated NK...
Thu Oct 15, 2020 10:05
Purpose: Pancreatic ductal adenocarcinoma (PDAC) is a lethal cancer with a survival rate less than 5%. Multiple chemotherapeutic drugs have been tested to improve patient prognosis; however, the clinical efficacy of these treatments is low. One of the most controversial family of drugs are the proteasome inhibitors, which have displayed promising effects in preclinical studies, but low clinical performance. Here, we unravel a specific transcriptomic signature that discriminates a subgroup of patients...
Thu Oct 15, 2020 10:05
Purpose: (4S)-4-(3-[18F]Fluoropropyl)-L-glutamic acid (18F-FSPG) is a radiopharmaceutical for PET imaging of system xC– activity, which can be upregulated in prostate cancer. We present data on the first evaluation of patients with newly diagnosed or recurrent prostate cancer with this radiopharmaceutical. Experimental Design: Ten patients with primary and 10 patients with recurrent prostate cancer were enrolled in this prospective multicenter study. After injection of 300 MBq of 18F-FSPG,...
Thu Oct 15, 2020 10:05
Purpose: Perivascular epithelioid cell tumors (PEComa) are rare mesenchymal neoplasms. mTOR inhibitors are the most active agents in PEComa and in patients progressing to mTOR inhibitors, other available therapies have limited benefit. Preclinical evidences showed a cross-talk between the mTOR pathway and estrogen receptor signaling. This provided a rationale for adding an antiestrogen treatment in female patients becoming resistant to mTOR inhibitors. Experimental Design: Since April 2018,...
Thu Oct 15, 2020 10:05
Purpose: Glioblastoma (GBM) is one of the deadliest cancers with no cure. While conventional MRI has been widely adopted to examine GBM clinically, accurate neuroimaging assessment of tumor histopathology for improved diagnosis, surgical planning, and treatment evaluation remains an unmet need in the clinical management of GBMs. Experimental Design: We employ a novel diffusion histology imaging (DHI) approach, combining diffusion basis spectrum imaging (DBSI) and machine learning, to detect,...
Thu Oct 15, 2020 10:05
A pan-cancer analysis of the human tumor coagulome and its link to the tumor immune microenvironment
Abstract Objective Solid tumors often establish a procoagulable state that can lead to venous thromboembolism (VTE). Although some of the key genes involved in this process are known, no previous study has compared the “coagulome”, i.e., the expression of coagulation/fibrinolysis genes, across different primary tumor types. It is also unclear whether the coagulome is associated with specific characteristics of the tumor microenvironment...
Thu Oct 15, 2020 03:00
Obesity is associated with life-threatening diseases and premature death and reduces life expectancy by 5 to 20 years. Bariatric surgery leads to durable weight loss and reduces the risk of cardiovascular disease, type 2 diabetes, and cancer. In 2007, we reported that bariatric surgery reduced…
Thu Oct 15, 2020 03:00
Upadacitinib is an oral, reversible Janus kinase (JAK) inhibitor with selectivity for JAK1 over JAK2, JAK3, and tyrosine kinase 2 that has been approved for the treatment of rheumatoid arthritis. Studies have shown remission with the use of upadacitinib in approximately 30% of patients regardless…
Thu Oct 15, 2020 03:00
Since the first cases of coronavirus disease 2019 (Covid-19) in Wuhan, China, in December 2019, pandemic illness has spread to millions of persons worldwide. An increased risk of severe disease and death has been noted among the elderly and among persons with preexisting medical conditions. No…
Wed Oct 14, 2020 03:00
Presentation of Case. Dr. Kevin L. Ard: A 63-year-old man was evaluated at this hospital in the spring because of fever, confusion, headache, garbled speech, fatigue, vision changes, lymphocytic pleocytosis, and an elevated protein level in the cerebrospinal fluid (CSF). Approximately 5 years…
Thu Oct 15, 2020 03:00
Future Oncology, Ahead of Print.
Wed Oct 14, 2020 12:01
Future Oncology, Ahead of Print.
Wed Oct 14, 2020 11:34
Future Oncology, Ahead of Print.
Wed Oct 14, 2020 11:29
Δεν υπάρχουν σχόλια:
Δημοσίευση σχολίου